Artrya Limited

As of June 30, 2026, Artrya Limited carries a market capitalization of 994.08M, placing it among publicly traded companies globally. Its enterprise value stands at 920.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Artrya Limited's next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2026, Artrya Limited has 162.96M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 32,321.70, and the price-to-book ratio stands at 12.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 32,862.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 920.15M versus a market cap of 994.08M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Artrya Limited maintains a current ratio of 15.72, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Artrya Limited posted a negative return on equity (ROE) of -50.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.20, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, Artrya Limited recorded 1,000.00 in income tax expense. The company reported a pretax loss of -25.18M and -25.18M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Artrya Limited's stock has declined approximately 20.66% over the past 52 weeks. The 50-day moving average sits at 3.75, while the 200-day moving average is 4.13.

Over the twelve months ended June 30, 2026, Artrya Limited generated 28,000.00 in revenue and converted that into -25.18M in net income, yielding earnings per share of -0.17. EBITDA reached -31.98M, while operating income came in at -33.24M.

As of June 30, 2026, Artrya Limited holds 74.17M in cash and equivalents against 247,000.00 in total debt, resulting in a net debt position of -44.02M. Total book value stands at 78.29M, with working capital of 74.70M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -118,710.71 and net profit margin of -89,939.29 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -7.95, meaning Artrya Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Artrya Limited has an Altman Z-Score of 82.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.